<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236962</url>
  </required_header>
  <id_info>
    <org_study_id>15-12</org_study_id>
    <nct_id>NCT02236962</nct_id>
  </id_info>
  <brief_title>Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment</brief_title>
  <official_title>Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is epidemic in Australia, and current preventative strategies have had limited
      success in alleviating this health crisis. While numerous options are available for treatment
      of obesity, most do not result in sustained weight reduction. Obesity results from an
      imbalance between energy intake and expenditure, therefore new methods that correct this
      imbalance are essential for effective long-term treatment. Rodent studies show that brown
      adipose tissue (BAT) can burn more energy than any other tissue in the body, therefore
      targeting BAT to increase its activity (energy burning rate) and quantity in humans is
      potentially a powerful tool for the treatment of obesity and related diseases. BAT has only
      recently been irrefutably identified in adult humans therefore little is known about how it
      functions in humans.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>brown adipose tissue activity</measure>
    <time_frame>3 years</time_frame>
    <description>measured via PET-CT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>lactose powder in equivalent capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sympathetic agonist and thiazolidinedione</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine, pioglitazone</intervention_name>
    <arm_group_label>Drug treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males aged 19 - 35 years

          -  Free of overt coronary disease (on history, medical examination and ECG)

          -  Unmedicated

          -  No major illness

          -  BMI &lt;27 kg/m2

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Smokers

          -  Participant in research projects involving ionising radiation within the past 5 years.

          -  Claustrophobia

          -  Fasting plasma glucose &gt; 6.0 mmol/L
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa F Formosa, B Sci</last_name>
    <phone>+61 9076 1652</phone>
    <email>m.formosa@alfred.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew L Carey, PhD</last_name>
    <phone>+61 8532 1251</phone>
    <email>andrew.carey@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa F Formosa, B Sci</last_name>
      <phone>+61 9076 6518</phone>
      <email>m.formosa@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Bronwyn A Kingwell, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2012</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

